|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM228753880 |
| 003 |
DE-627 |
| 005 |
20231224080635.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.05.011
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0762.xml
|
| 035 |
|
|
|a (DE-627)NLM228753880
|
| 035 |
|
|
|a (NLM)23811319
|
| 035 |
|
|
|a (PII)S1521-6616(13)00131-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liang, Spencer C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.09.2013
|
| 500 |
|
|
|a Date Revised 08.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a In this report, a Treg-depleting anti-FR4 antibody is combined with a GM-CSF-secreting tumor cell immunotherapy (GVAX) for treatment of melanoma-bearing animals. Median survival time (MST) of animals treated with GVAX was 41 days, compared to a MST of 32 days in untreated animals. Anti-FR4 monotherapy had no effect on MST. Combination of anti-FR4 and GVAX significantly prolonged MST to 55 days, suggesting that these two agents can function cooperatively. Combination therapy increased expression of IFN-γ and granzyme B by CD8 T cells. In contrast to anti-CD25-mediated Treg depletion, administration of anti-FR4 after GVAX did not reduce efficacy, suggesting that anti-FR4 does not deplete effector cells induced by GVAX. Triple combination of a blocking CTLA4 antibody with GVAX and anti-FR4 further enhanced overall survival and reduced growth of well-established melanomas. Considered together, anti-FR4 antibody and GVAX may be a promising approach for the treatment of patients with cancer
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Cancer immunotherapy
|
| 650 |
|
4 |
|a Costimulation
|
| 650 |
|
4 |
|a T cells
|
| 650 |
|
4 |
|a Tregs
|
| 650 |
|
7 |
|a Antibodies
|2 NLM
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Cell Surface
|2 NLM
|
| 650 |
|
7 |
|a folate receptor 4, mouse
|2 NLM
|
| 650 |
|
7 |
|a Granulocyte-Macrophage Colony-Stimulating Factor
|2 NLM
|
| 650 |
|
7 |
|a 83869-56-1
|2 NLM
|
| 700 |
1 |
|
|a Moskalenko, Marina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Van Roey, Melinda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jooss, Karin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 148(2013), 2 vom: 15. Aug., Seite 287-98
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:148
|g year:2013
|g number:2
|g day:15
|g month:08
|g pages:287-98
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.05.011
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 148
|j 2013
|e 2
|b 15
|c 08
|h 287-98
|